Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN funding

This article was originally published in The Tan Sheet

Executive Summary

The Senate Appropriations Committee recommends that FDA's Center for Food Safety & Applied Nutrition receive $5.3 mil. in funding for its Adverse Event Report System in fiscal year 2007 - a figure that is $1 mil. higher than the President's budget request, according to a committee report released June 22. The proposed increase may be related to the June 21 introduction of legislation that would make serious adverse event reporting mandatory for dietary supplement firms. The committee "has recommended funding to continue enforcement of the provisions contained in DSHEA," the report adds. "It is the Committee's intent that these funds be prioritized by the agency to step up activities against products that are clearly in violation of DSHEA." The senators also are "concerned" that dietary supplement good manufacturing practices have not yet been released by FDA and "direct" the agency to issue them. The Agriculture Appropriations bill now heads to the full Senate after being passed by the committee...

You may also be interested in...

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’

Health And Wellness Trademark Review 22 September, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

India’s Draft Guidelines For COVID-19 Vaccines Follow WHO, US Lead

India has rolled out draft guidelines for development of vaccines with special focus on COVID-19 vaccines, drawing from those of other regulatory bodies and the WHO. Experts suggest the primary efficacy endpoint of minimum 50% is acceptable given that vaccines against respiratory diseases are difficult to develop though not necessarily enough to snuff out a pandemic.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts